{"id":2014,"date":"2026-02-04T15:36:27","date_gmt":"2026-02-04T14:36:27","guid":{"rendered":"https:\/\/studienportal-eierstockkrebs.de\/study-objective-achieved-results-of-the-rosella-study\/"},"modified":"2026-02-20T11:28:48","modified_gmt":"2026-02-20T10:28:48","slug":"study-objective-achieved-results-of-the-rosella-study","status":"publish","type":"post","link":"https:\/\/studienportal-eierstockkrebs.de\/en\/study-objective-achieved-results-of-the-rosella-study\/","title":{"rendered":"Study objective achieved! &#8211; Results of the ROSELLA study"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"2014\" class=\"elementor elementor-2014 elementor-1849\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e438c86 e-flex e-con-boxed e-con e-parent\" data-id=\"e438c86\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2cf51b7 elementor-widget elementor-widget-heading\" data-id=\"2cf51b7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\"><strong>New findings on the treatment of platinum-resistant ovarian cancer<\/strong> - results of the ROSELLA study<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-070f551 elementor-widget elementor-widget-text-editor\" data-id=\"070f551\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>At the end of January, the pharmaceutical company Corcept Therapeutics published a press release on the positive results of the ROSELLA study!<\/p><p data-start=\"310\" data-end=\"622\">This study investigated whether the combination of the drug <strong data-start=\"476\" data-end=\"492\">Relacorilant<\/strong> and the chemotherapy <strong data-start=\"515\" data-end=\"533\">nab-paclitaxel<\/strong> can improve the survival of patients with <strong data-start=\"569\" data-end=\"605\">platinum-resistant ovarian cancer<\/strong>.<\/p><h3 data-start=\"624\" data-end=\"660\"><strong data-start=\"628\" data-end=\"660\">What was the study about?<\/strong><\/h3><p data-start=\"661\" data-end=\"924\">Platinum-resistant ovarian cancer means that the tumor has continued to grow despite platinum-based chemotherapy and only responds to a limited extent to standard therapies. Such patients often have a poor prognosis and only limited treatment options. <\/p><p data-start=\"926\" data-end=\"1005\">In the ROSELLA study, <strong data-start=\"955\" data-end=\"975\">381 patients<\/strong> worldwide were randomly divided into two groups:<\/p><ul data-start=\"1006\" data-end=\"1130\"><li data-start=\"1006\" data-end=\"1079\"><p data-start=\"1008\" data-end=\"1079\">One group received <strong data-start=\"1028\" data-end=\"1053\">nab-paclitaxel alone<\/strong> (standard chemotherapy),<\/p><\/li><li data-start=\"1080\" data-end=\"1130\"><p data-start=\"1082\" data-end=\"1130\">the other <strong data-start=\"1093\" data-end=\"1129\">nab-Paclitaxel plus Relacorilant<\/strong>.<\/p><\/li><\/ul><h3 data-start=\"1132\" data-end=\"1167\"><strong data-start=\"1136\" data-end=\"1167\">What did the study show?<\/strong><\/h3><p data-start=\"1169\" data-end=\"1448\">\ud83d\udccc <strong data-start=\"1172\" data-end=\"1204\">1. Lower risk of death<\/strong><br data-start=\"1204\" data-end=\"1207\">Patients who received Relacorilant in addition to chemotherapy had a <strong data-start=\"1289\" data-end=\"1329\">35% lower risk of death<\/strong> than those who received chemotherapy alone. This means that the new combination significantly prolonged <strong data-start=\"1419\" data-end=\"1438\">overall survival<\/strong>. <\/p><p data-start=\"1450\" data-end=\"1642\">\ud83d\udccc <strong data-start=\"1453\" data-end=\"1482\">2. Longer survival time<\/strong><br data-start=\"1482\" data-end=\"1485\">On average, patients with Relacorilant lived for 16.0 months compared to 11.9 months with chemotherapy alone &#8211; i.e. around <strong data-start=\"1622\" data-end=\"1641\">4 months longer<\/strong>.<\/p><p data-start=\"1644\" data-end=\"1865\">\ud83d\udccc <strong data-start=\"1647\" data-end=\"1691\">3. better progression-free survival<\/strong><br data-start=\"1691\" data-end=\"1694\">It has previously been shown that the combination also improves the time until the disease progresses &#8211; i.e. the period in which tumors do not grow any further.<\/p><p data-start=\"1867\" data-end=\"2163\">\ud83d\udccc <strong data-start=\"1870\" data-end=\"1892\">4. well tolerated<\/strong><br data-start=\"1892\" data-end=\"1895\">Important: The combination was well tolerated and severe <strong>side effects<\/strong> <strong data-start=\"1979\" data-end=\"2001\">did not occur more frequently<\/strong> than with chemotherapy alone. This means that Relacorilant brings its benefits without noticeably worsening safety for patients. <\/p><p data-start=\"2165\" data-end=\"2437\">\ud83d\udccc <strong data-start=\"2168\" data-end=\"2204\">5. no biomarker restriction<\/strong><br data-start=\"2204\" data-end=\"2207\">Unlike with some other therapies, it was not necessary to select patients according to a specific tumor biomarker in this study &#8211; the benefits of the therapy were <strong>independent of certain tumor characteristics<\/strong>.<\/p><h3 data-start=\"2439\" data-end=\"2496\"><strong data-start=\"2443\" data-end=\"2496\">What does this mean for patients in Germany?<\/strong><\/h3><p data-start=\"2498\" data-end=\"2784\"><strong data-start=\"2501\" data-end=\"2551\">Promising new treatment option in sight<\/strong><br data-start=\"2551\" data-end=\"2554\">The results are particularly important because they show for the first time that an additional substance not only delays progression but also prolongs overall survival &#8211; without additional safety issues.<\/p><p data-start=\"2786\" data-end=\"3192\"><strong data-start=\"2789\" data-end=\"2825\">Regulatory submissions currently underway<\/strong><br data-start=\"2825\" data-end=\"2828\">&#8211; In the US, the Food and Drug Administration (FDA) is currently reviewing Corcept&#8217;s application for approval of Relacorilant for platinum-resistant ovarian cancer; a result is expected by July 11, 2026.<br data-start=\"3043\" data-end=\"3046\">&#8211; In Europe &#8211; including Germany &#8211; the application is also currently being evaluated by the European Medicines Agency (EMA).<\/p><p data-start=\"3194\" data-end=\"3477\">\u27a1\ufe0f <strong data-start=\"3197\" data-end=\"3257\">Until approval, it will not remain a standard in Germany<\/strong><br data-start=\"3257\" data-end=\"3260\">Until Relacorilant is officially approved, this combination is <strong data-start=\"3335\" data-end=\"3390\">not yet part of the regular treatment guidelines<\/strong> in Germany. But the current data are an important step in this direction. <\/p><p><span style=\"color: #29b8ce;\"><strong>Source:<\/strong> <\/span><a href=\"https:\/\/ir.corcept.com\/news-releases\/news-release-details\/overall-survival-primary-endpoint-met-corcepts-pivotal-phase-3\/\" target=\"_blank\" rel=\"noopener\">Press release from Corcept<\/a> (the article is in English)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>New findings on the treatment of platinum-resistant ovarian cancer &#8211; results of the ROSELLA study At the end of January, the pharmaceutical company Corcept Therapeutics published a press release on the positive results of the ROSELLA study! This study investigated whether the combination of the drug Relacorilant and the chemotherapy nab-paclitaxel can improve the survival [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":2393,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[30],"tags":[],"class_list":["post-2014","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/posts\/2014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/comments?post=2014"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/posts\/2014\/revisions"}],"predecessor-version":[{"id":2016,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/posts\/2014\/revisions\/2016"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/media\/2393"}],"wp:attachment":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/media?parent=2014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/categories?post=2014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/tags?post=2014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}